These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 8682658)

  • 1. Apolipoprotein-AI-containing particles and atherosclerosis.
    Fruchart JC; Castro G; Duriez P
    Isr J Med Sci; 1996 Jun; 32(6):498-502. PubMed ID: 8682658
    [No Abstract]   [Full Text] [Related]  

  • 2. Lp A-I and niacin: new views of an antiatherogenic duo.
    Saucan L; Brinton EA
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1707-9. PubMed ID: 11701453
    [No Abstract]   [Full Text] [Related]  

  • 3. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
    Holvoet P; Danloy S; Deridder E; Lox M; Bernar H; Dhoest A; Collen D
    J Clin Invest; 1998 Jul; 102(2):379-85. PubMed ID: 9664079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism.
    Watts GF; Chan DC
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1892-5. PubMed ID: 18946055
    [No Abstract]   [Full Text] [Related]  

  • 5. ApoA-II versus ApoA-I: two for one is not always a good deal.
    Castellani LW; Lusis AJ
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):1870-2. PubMed ID: 11742857
    [No Abstract]   [Full Text] [Related]  

  • 6. Apolipoprotein A1 and B.
    Sniderman AD; Marcovina SM
    Clin Lab Med; 2006 Dec; 26(4):733-50. PubMed ID: 17110237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.
    Zambon A; Brown BG; Deeb SS; Brunzell JD
    J Intern Med; 2006 May; 259(5):473-80. PubMed ID: 16629853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of treatment on lipoprotein metabolism. II. How to treat?].
    Cybulska B
    Przegl Lek; 1987; 44(6):520-4. PubMed ID: 3685440
    [No Abstract]   [Full Text] [Related]  

  • 10. Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
    Pérez-Méndez O; Duhal N; Lacroix B; Bonte JP; Fruchart JC; Luc G
    Clin Chim Acta; 2006 Jun; 368(1-2):149-54. PubMed ID: 16487502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein AI as therapy for atherosclerosis: does the future of preventive cardiology include weekly injections of the HDL protein?
    Fazio S; Linton MF
    Mol Interv; 2003 Dec; 3(8):436-40. PubMed ID: 14993451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoproteins: multifunctional vanguards of the cardiovascular system.
    Marcil M; O'Connell B; Krimbou L; Genest J
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):417-30. PubMed ID: 15151487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An A+ for macrophages in reducing atherosclerosis?
    Smith JD
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1710-1. PubMed ID: 11701454
    [No Abstract]   [Full Text] [Related]  

  • 14. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis.
    Sethi AA; Amar M; Shamburek RD; Remaley AT
    Curr Opin Investig Drugs; 2007 Mar; 8(3):201-12. PubMed ID: 17408115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.
    Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P
    Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure to generate atheroprotective apolipoprotein AI phenotypes using synthetic RNA/DNA oligonucleotides (chimeraplasts).
    Manzano A; Mohri Z; Sperber G; Ogris M; Graham I; Dickson G; Owen JS
    J Gene Med; 2003 Sep; 5(9):795-802. PubMed ID: 12950070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport.
    Duffy D; Rader DJ
    Circulation; 2006 Feb; 113(8):1140-50. PubMed ID: 16505192
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia.
    Belalcazar LM; Merched A; Carr B; Oka K; Chen KH; Pastore L; Beaudet A; Chan L
    Circulation; 2003 Jun; 107(21):2726-32. PubMed ID: 12742997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How HDL protects against atheroma.
    Durrington PN
    Lancet; 1993 Nov; 342(8883):1315-6. PubMed ID: 7901633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.